Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E16.44 EPS (ttm)20.71 Insider Own20.20% Shs Outstand110.47M Perf Week-7.41%
Market Cap37.61B Forward P/E13.55 EPS next Y25.13 Insider Trans-0.02% Shs Float79.03M Perf Month-13.81%
Income2.38B PEG1.48 EPS next Q5.44 Inst Own73.20% Short Float2.65% Perf Quarter-15.14%
Sales6.71B P/S5.60 EPS this Y57.40% Inst Trans0.95% Short Ratio2.81 Perf Half Y-12.66%
Book/sh81.00 P/B4.20 EPS next Y9.44% ROA23.40% Target Price430.19 Perf Year7.74%
Cash/sh25.44 P/C13.39 EPS next 5Y11.10% ROE32.20% 52W Range281.89 - 442.00 Perf YTD-8.85%
Dividend- P/FCF20.76 EPS past 5Y40.30% ROI24.90% 52W High-23.14% Beta1.13
Dividend %- Quick Ratio3.90 Sales past 5Y26.10% Gross Margin93.50% 52W Low20.52% ATR11.34
Employees7400 Current Ratio4.50 Sales Q/Q21.80% Oper. Margin37.80% RSI (14)28.26 Volatility4.05% 2.98%
OptionableYes Debt/Eq0.00 EPS Q/Q54.50% Profit Margin36.40% Rel Volume0.79 Prev Close340.46
ShortableYes LT Debt/Eq0.08 EarningsMay 07 BMO Payout0.00% Avg Volume744.43K Price339.72
Recom2.50 SMA20-11.59% SMA50-15.79% SMA200-11.97% Volume130,550 Change-0.22%
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Apr-24-19 03:42PM  Why Investors Should Buy the Dip in MRK Stock InvestorPlace
Apr-22-19 06:59PM  How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)
01:54PM  This Is Why You Shouldnt Count Regeneron Stock Out InvestorPlace
08:30AM  A Bullish Play on Netflix
Apr-18-19 03:17PM  Health-care drama has now spread to biopharma stocks MarketWatch
Apr-16-19 07:13PM  Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Zacks
11:46AM  Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Simply Wall St.
10:57AM  Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA Zacks
Apr-15-19 04:49PM  Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Zacks
08:30AM  Stalking an Entry in Regeneron Pharmaceuticals
Apr-12-19 09:42AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 09:03AM  Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks
Apr-08-19 04:01PM  Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019 PR Newswire
01:55PM  Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics Benzinga
11:13AM  Regeneron forays into gene-silencing therapies with Alnylam tie-up Reuters
09:10AM  Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals
07:11AM  Alnylam, Regeneron to partner for RNAi treatments Reuters
07:00AM  Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases PR Newswire
07:00AM  Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases Business Wire
Apr-04-19 10:36AM  Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks
Apr-03-19 10:00AM  Allergan's AMD Drug Lowers Inflammation in Phase III Study Zacks
Apr-02-19 10:51AM  Inovio Closes Enrollment in Brain Cancer Study Before Time Zacks
Mar-28-19 08:20AM  Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy? Insider Monkey
Mar-27-19 10:52AM  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis Simply Wall St.
Mar-25-19 04:26PM  Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
07:40AM  Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-24-19 09:00AM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Mar-21-19 09:46AM  Biogen shares tank nearly 30% after pulling key Alzheimers drug trial Yahoo Finance
Mar-20-19 07:07AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Mar-18-19 06:59PM  Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent Zacks
11:28AM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
11:15AM  Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop Bloomberg
Mar-15-19 04:02PM  Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease GlobeNewswire
03:15PM  Try These 3 Steps To Compound Your Profits In The Best Growth Stocks Investor's Business Daily
Mar-13-19 10:55AM  10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run Zacks
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
10:03AM  Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down Zacks
07:00AM  Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19 PR Newswire
05:04AM  Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 09:56PM  Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem PR Newswire
03:22PM  Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Zacks
11:36AM  FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents PR Newswire
Mar-11-19 04:32PM  Regeneron/Sanofi wins U.S. approval for expanded use of skin drug Reuters
03:45PM  FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents PR Newswire
03:44PM  FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents PR Newswire
03:29PM  Regeneron/Sanofi skin disease drug cleared for use in U.S. teens Reuters
10:07AM  Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps Zacks
01:00AM  New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community PR Newswire
Mar-08-19 04:32PM  Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock? Investor's Business Daily
04:01PM  Regeneron Announces Upcoming Investor Conference Call PR Newswire
09:30AM  Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue? Zacks
01:02AM  Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps GlobeNewswire
12:59AM  FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps PR Newswire
Mar-06-19 10:26AM  Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More Zacks
Mar-05-19 11:08AM  Does Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Have A Good P/E Ratio? Simply Wall St.
Mar-04-19 05:15PM  Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion Zacks
11:50AM  Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Benzinga
07:11AM  Biotech stocks are going wild, and these two could be your best bet for a bigger breakout CNBC
Mar-01-19 08:35AM  CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication PR Newswire
08:15AM  Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication GlobeNewswire
06:59AM  New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis PR Newswire
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
08:10AM  Analysis: Positioning to Benefit within Kohl's, Regeneron Pharmaceuticals, Moody's, Ashland Global, Waste Management, and Newmark Group Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-26-19 01:28PM  Big Pharma faces the Senate in drug price hearings Yahoo Finance Video
10:47AM  Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor Zacks
07:56AM  The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote Benzinga
Feb-25-19 05:48PM  Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug Reuters
05:22PM  Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies PR Newswire
05:16PM  Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies GlobeNewswire
12:46PM  Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps GlobeNewswire
12:44PM  Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) PR Newswire
Feb-22-19 02:46PM  bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Feb-21-19 05:35PM  Regeneron CEO Has Rewarded Shareholders Handsomely
Feb-20-19 05:59PM  Edited Transcript of REGN earnings conference call or presentation 6-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
09:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
08:42AM  Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study Zacks
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-15-19 04:41PM  U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor PR Newswire
Feb-14-19 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-12-19 09:30AM  Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year? Zacks
08:56AM  Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60% Zacks
08:30AM  New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-11-19 12:39PM  Regeneron will spend up to $490 million on manufacturing, labs this year American City Business Journals
11:45AM  Regenerons 60% Price Cut Shows Heat Is Still on Drug Companies
07:18AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 percent Reuters
07:00AM  Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price PR Newswire
07:00AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 pct Reuters
06:59AM  Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price PR Newswire
12:24AM  [$$] Sanofi and Regeneron cut price of Praluent by 60% Financial Times
Feb-09-19 04:30PM  One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium PR Newswire
Feb-08-19 10:25AM  The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National Zacks
07:06AM  What Can We Expect From Regeneron Pharmaceuticals, Inc.s (NASDAQ:REGN) Earnings In The Year Ahead? Simply Wall St.
Feb-07-19 08:48PM  Regeneron Pharmaceuticals Inc (REGN) Files 10-K for the Fiscal Year Ended on December 31, 2018
03:41PM  Top Stock Reports for Chevron, CSX Corporation & Regeneron Zacks
08:32AM  Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth Zacks
06:00AM  Regeneron profits double ahead of $800 million expansion American City Business Journals
Feb-06-19 05:32PM  Regeneron Pharmaceuticals Inc (REGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM